171 Paclitaxel (TAX) and carboplatin (CBDA) in advanced SCLC: A phase II study

Deppermann, Karl-Matthias; Kurzeja, A; Lichey, J; Serke, Monika; Riedel, U.; Loddenkemper, R.; Oehm, C; Klöckner, T.; Holz, Josefin-Beate

doi:10.1016/s0169-5002(97)89450-0

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of carboplatin/paclitaxel/etoposide has been evaluated in several trials of patients with SCLC (Table 7) [43][44][45][46][47][48]. The results of these clinical trials are encouraging, with overall response rates ranging from 61% to 84% in patients with ED and 81% to 98% in LD.…”

Section: Carboplatin/paclitaxel/etoposide Regimens For Sclcmentioning

confidence: 99%

Carboplatin in the Treatment of Small Cell Lung Cancer

Brahmer¹,

Ettinger²

1998

The Oncologist

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) will account for approximately 20%‐25% of the 171,500 estimated new lung cancer cases in 1998. Combination cytotoxic therapies have yielded the best response rates in SCLC patients. Cisplatin in combination with etoposide is used routinely in the treatment of SCLC. Because of cisplatin's nonhematologic toxicities, carboplatin was developed and has far fewer nonhematologic toxicities. Carboplatin in combination with etoposide has been shown to be as effective as, but less toxic than, cisplatin/etoposide. Moreover, carboplatin/etoposide is a viable combination in the treatment of the elderly with SCLC, who can readily tolerate this combination. Concurrent radiation therapy with carboplatin and etoposide in patients with limited SCLC disease can be given safely and effectively. Carboplatin has been combined with several different chemotherapeutic agents, including ifosfamide, and, more recently, paclitaxel in hopes of improving the response rates and overall survival. In order to try to dose intensify carboplatin‐based regimens, peripheral blood stem cells have been used to decrease the hematologic toxicities. Further studies are warranted to investigate these therapies as well as newer carboplatin combinations.

show abstract

Section: Carboplatin/paclitaxel/etoposide Regimens For Sclcmentioning

confidence: 99%

Carboplatin in the Treatment of Small Cell Lung Cancer

Brahmer¹,

Ettinger²

1998

The Oncologist

View full text Add to dashboard Cite

show abstract

“…However, ours being a phase 2 study design, we cannot exclude a falsenegative result. Nevertheless, our data together with earlier studies (Deppermann, 1999;Thomas, 1999) indicate that the association of paclitaxel with platinum compounds in 2-drug combinations is not a good candidate for phase 3 trials. A promising approach might be to add paclitaxel to standard drugs, in 3-drug combinations, e.g.…”

Section: Discussionmentioning

confidence: 51%

“…Thomas and colleagues (1999) studied a regimen theoretically more intensive than ours (AUC 6 carboplatin and 200 mg/m 2 paclitaxel as 3-h infusion given every 3 weeks); data reported for 35/46 enrolled patients showed a response rate of 67%, 10% complete responses and a median survival of 6 months. Deppermann et al (1999) using the same schedule as Thomas et al obtained a 61% response rate in 75 patients, with 7% complete responses and a median survival of 12 months. Toxicity was important in the latter study: grade 3-4 neutropenia in 43% of cycles and grade 2-3 peripheral neurotoxicity in 29% of cycles.…”

Section: Discussionmentioning

confidence: 78%

Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study

Gridelli

Manzione

Perrone³

et al. 2001

Br J Cancer

View full text Add to dashboard Cite

A multicentre phase 2 trial (single-stage design) was undertaken to test the efficacy and toxicity of carboplatin (AUC 6 according to Calvert) plus paclitaxel (175 mg/m 2 3-h infusion) every 4 weeks in the first line treatment of patients affected by extensive small cell lung cancer. The primary end-point of the trial was the objective response rate. 31 objective responses among 50 patients were considered necessary to proceed to a phase 3 trial. 48 patients were enrolled (median age 59 years). Treatment was very well tolerated. 3 patients (6.2%) had a complete response and 23 (47.9%) a partial response, for an overall response rate of 54.2% (95% CI: 39.2–68.6) Median time to progression was 5.7 months (95% CI: 5.2–6.2). Median survival was 9.6 months (95% CI: 7.2–14.6), with a median follow-up time of alive patients of 12 months. At 1 year, the probability of being progression-free or alive was 0.16 and 0.43, respectively. In conclusion, carboplatin plus paclitaxel as given in the present study is very well tolerated but not sufficiently active to warrant phase 3 comparison with standard chemotherapy regimens. © 2001 Cancer Research Campaign http://www.bjcancer.com

show abstract

Current Management and New Leads in Small Cell Lung Cancer

Greco¹,

Hainsworth²

1999

Progress in Anti-Cancer Chemotherapy

View full text Add to dashboard Cite

171 Paclitaxel (TAX) and carboplatin (CBDA) in advanced SCLC: A phase II study

Cited by 3 publications

References 0 publications

Carboplatin in the Treatment of Small Cell Lung Cancer

Carboplatin in the Treatment of Small Cell Lung Cancer

Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study

Current Management and New Leads in Small Cell Lung Cancer

Contact Info

Product

Resources

About